Please use this identifier to cite or link to this item:
Title: A consensus statement on the use of biosimilar medicines in hematology in Australia.
Austin Authors: Gregory, Gareth P;Carrington, Christine;Cheah, Chan Y;Hawkes, Eliza A ;Irving, Ian M;Siderov, Jim ;Opat, Stephen
Affiliation: Monash Haematology, Monash Health, Clayton, Victoria, Australia
Department of Pharmacy, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Medical School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia
Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine WA, Nedlands, Western Australia, Australia
Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia
Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia
School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia
Eastern Health, Melbourne, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Icon Group, Brisbane, Queensland, Australia
The Wesley Hospital, Auchenflower, Queensland, Australia
Issue Date: Aug-2020 2020-04-14
Publication information: Asia-Pacific journal of clinical oncology 2020; 16(4): 211-221
Abstract: Despite their availability for over a decade, the exact nature of biosimilar medicines is still poorly understood with paucity of clear treatment guidelines for their use in clinical practice in Australia. Although hematologists have had experience with biosimilars in the setting of supportive care, with the approval of the first biosimilar rituximab in hematological malignancies, it is important to revisit this topic. To inform the use of biosimilar medicines in clinical practice, we have developed a consensus statement from an Expert Panel of Australian hematologists, oncologists, and cancer pharmacists. These recommendations address the approach to use of biosimilar products in place of the corresponding reference medicine in a number of different clinical contexts. Our recommendations are based on the premise that biosimilar medicines can be considered therapeutically equivalent to their reference brand and used in a similar way to the reference product in any approved indication. We advocate for local approaches to the provision of patient information, dispensing of the intended brand and pharmacovigilance, to be developed in consultation with local hematologists and aim to improve confidence in the appropriate use of biosimilar medicines and their expected outcomes among hematologists.
DOI: 10.1111/ajco.13337
ORCID: 0000-0002-4170-0682
PubMed URL: 32285612
Type: Journal Article
Subjects: biosimilars
consensus statement
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.